681 related articles for article (PubMed ID: 11527957)
1. VEGF-initiated blood-retinal barrier breakdown in early diabetes.
Qaum T; Xu Q; Joussen AM; Clemens MW; Qin W; Miyamoto K; Hassessian H; Wiegand SJ; Rudge J; Yancopoulos GD; Adamis AP
Invest Ophthalmol Vis Sci; 2001 Sep; 42(10):2408-13. PubMed ID: 11527957
[TBL] [Abstract][Full Text] [Related]
2. Sensitive blood-retinal barrier breakdown quantitation using Evans blue.
Xu Q; Qaum T; Adamis AP
Invest Ophthalmol Vis Sci; 2001 Mar; 42(3):789-94. PubMed ID: 11222542
[TBL] [Abstract][Full Text] [Related]
3. Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats.
Kusari J; Zhou S; Padillo E; Clarke KG; Gil DW
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5152-9. PubMed ID: 17962468
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of vitreoretinal VEGF elevation and blood-retinal barrier breakdown in streptozotocin-induced diabetic rats by brimonidine.
Kusari J; Zhou SX; Padillo E; Clarke KG; Gil DW
Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):1044-51. PubMed ID: 19710406
[TBL] [Abstract][Full Text] [Related]
5. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas.
Murata T; Nakagawa K; Khalil A; Ishibashi T; Inomata H; Sueishi K
Lab Invest; 1996 Apr; 74(4):819-25. PubMed ID: 8606491
[TBL] [Abstract][Full Text] [Related]
6. VEGF164 is proinflammatory in the diabetic retina.
Ishida S; Usui T; Yamashiro K; Kaji Y; Ahmed E; Carrasquillo KG; Amano S; Hida T; Oguchi Y; Adamis AP
Invest Ophthalmol Vis Sci; 2003 May; 44(5):2155-62. PubMed ID: 12714656
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes.
Gilbert RE; Vranes D; Berka JL; Kelly DJ; Cox A; Wu LL; Stacker SA; Cooper ME
Lab Invest; 1998 Aug; 78(8):1017-27. PubMed ID: 9714188
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease.
Vinores SA; Youssri AI; Luna JD; Chen YS; Bhargave S; Vinores MA; Schoenfeld CL; Peng B; Chan CC; LaRochelle W; Green WR; Campochiaro PA
Histol Histopathol; 1997 Jan; 12(1):99-109. PubMed ID: 9046048
[TBL] [Abstract][Full Text] [Related]
9. Normalization of retinal vascular permeability in experimental diabetes with genistein.
Nakajima M; Cooney MJ; Tu AH; Chang KY; Cao J; Ando A; An GJ; Melia M; de Juan E
Invest Ophthalmol Vis Sci; 2001 Aug; 42(9):2110-4. PubMed ID: 11481279
[TBL] [Abstract][Full Text] [Related]
10. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo.
Joussen AM; Poulaki V; Qin W; Kirchhof B; Mitsiades N; Wiegand SJ; Rudge J; Yancopoulos GD; Adamis AP
Am J Pathol; 2002 Feb; 160(2):501-9. PubMed ID: 11839570
[TBL] [Abstract][Full Text] [Related]
11. Endothelial F-actin cytoskeleton in the retinal vasculature of normal and diabetic rats.
Yu PK; Yu DY; Cringle SJ; Su EN
Curr Eye Res; 2005 Apr; 30(4):279-90. PubMed ID: 16020258
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products.
Kaji Y; Usui T; Ishida S; Yamashiro K; Moore TC; Moore J; Yamamoto Y; Yamamoto H; Adamis AP
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):858-65. PubMed ID: 17251488
[TBL] [Abstract][Full Text] [Related]
13. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown.
Edelman JL; Lutz D; Castro MR
Exp Eye Res; 2005 Feb; 80(2):249-58. PubMed ID: 15670803
[TBL] [Abstract][Full Text] [Related]
14. Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization.
Castro MR; Lutz D; Edelman JL
Exp Eye Res; 2004 Aug; 79(2):275-85. PubMed ID: 15325574
[TBL] [Abstract][Full Text] [Related]
15. Role of alpha 4 integrin (CD49d) in the pathogenesis of diabetic retinopathy.
Iliaki E; Poulaki V; Mitsiades N; Mitsiades CS; Miller JW; Gragoudas ES
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4898-904. PubMed ID: 19553613
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy.
Mathews MK; Merges C; McLeod DS; Lutty GA
Invest Ophthalmol Vis Sci; 1997 Dec; 38(13):2729-41. PubMed ID: 9418725
[TBL] [Abstract][Full Text] [Related]
17. Quantitative MR imaging study of intravitreal sustained release of VEGF in rabbits.
Alikacem N; Yoshizawa T; Nelson KD; Wilson CA
Invest Ophthalmol Vis Sci; 2000 May; 41(6):1561-9. PubMed ID: 10798677
[TBL] [Abstract][Full Text] [Related]
18. Effects of peroxisome proliferator-activated receptor gamma and its ligand on blood-retinal barrier in a streptozotocin-induced diabetic model.
Muranaka K; Yanagi Y; Tamaki Y; Usui T; Kubota N; Iriyama A; Terauchi Y; Kadowaki T; Araie M
Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4547-52. PubMed ID: 17003451
[TBL] [Abstract][Full Text] [Related]
19. Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats.
Rota R; Chiavaroli C; Garay RP; Hannaert P
Eur J Pharmacol; 2004 Jul; 495(2-3):217-24. PubMed ID: 15249173
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier.
Saishin Y; Saishin Y; Takahashi K; Melia M; Vinores SA; Campochiaro PA
J Cell Physiol; 2003 May; 195(2):210-9. PubMed ID: 12652648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
